SAHA

• CAT Number: A000479
• CAS Number: 149647-78-9
• Molecular Formula: C₁₄H₂₀N₂O₃
• Molecular Weight: 264.3
• Purity: ≥95%
• Target: HDAC
• Solubility: >4.4mg/mL in DMSO
• Storage: -20°C
• InChI: InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
• InChIKey: WAEXFXRVDQXREF-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

Vorinostat, also known as suberanilohydroxamic acid, MK-0683 and SAHA, is a potent and selective inhibitor of histone deacetylases (HDACs). Vorinostat has been shown to bind to the active site of histone deacetylases and act as a chelator for Zinc ions also found in the active site of histone deacetylases. Vorinostat/’s inhibition of histone deacetylases results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation. Vorinostat was approved for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines.

Reference

1: Bernhart E, Stuendl N, Kaltenegger H, Windpassinger C, Donohue N, Leithner A,
Lohberger B. Histone deacetylase inhibitors vorinostat and panobinostat induce G1
cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.
Oncotarget. 2017 Aug 24;8(44):77254-77267. doi: 10.18632/oncotarget.20460.
eCollection 2017 Sep 29. PubMed PMID: 29100385; PubMed Central PMCID: PMC5652778.

2: Kwak TW, Lee HL, Song YH, Kim C, Kim J, Seo SJ, Jeong YI, Kang DH.
Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for
inhibition of cholangiocarcinoma cells. Int J Nanomedicine. 2017 Oct
17;12:7669-7680. doi: 10.2147/IJN.S141920. eCollection 2017. PubMed PMID:
29089762; PubMed Central PMCID: PMC5655133.

3: Masadeh MM, Alzoubi KH, Al-Azzam SI, Al-Buhairan AM. Possible involvement of
ROS generation in vorinostat pretreatment induced enhancement of the
antibacterial activity of ciprofloxacin. Clin Pharmacol. 2017 Oct 17;9:119-124.
doi: 10.2147/CPAA.S148448. eCollection 2017. PubMed PMID: 29081676; PubMed
Central PMCID: PMC5652917.

4: Nanavati C, Ruszaj D, Mager DE. Cell Signaling Model Connects Vorinostat
Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts. CPT
Pharmacometrics Syst Pharmacol. 2017 Oct 17. doi: 10.1002/psp4.12246. [Epub ahead
of print] PubMed PMID: 29045072.

5: Holtan SG, Weisdorf DJ. Vorinostat is victorious in GVHD prevention. Blood.
2017 Oct 12;130(15):1690-1691. doi: 10.1182/blood-2017-08-802249. PubMed PMID:
29025718.

6: Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon
KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee
EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY;
Alliance for Clinical Trials in Oncology and ABTC. Phase I/II Trial of Vorinostat
Combined with Temozolomide and Radiation Therapy for Newly Diagnosed
Glioblastoma: Final Results of Alliance N0874/ABTC 02. Neuro Oncol. 2017 Aug 22.
doi: 10.1093/neuonc/nox161. [Epub ahead of print] PubMed PMID: 29016887.

7: Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T. A
physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the
histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients
and its application for dose specification. Cancer Chemother Pharmacol. 2017
Nov;80(5):1013-1026. doi: 10.1007/s00280-017-3447-x. Epub 2017 Oct 7. PubMed
PMID: 28988277.

8: Hay JF, Lappin K, Liberante F, Kettyle LM, Matchett KB, Thompson A, Mills KI.
Integrated analysis of the molecular action of Vorinostat identifies
epi-sensitised targets for combination therapy. Oncotarget. 2017 Jul
1;8(40):67891-67903. doi: 10.18632/oncotarget.18910. eCollection 2017 Sep 15.
PubMed PMID: 28978082; PubMed Central PMCID: PMC5620222.

9: Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G,
Yen Y. Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516-x. [Epub ahead
of print] PubMed PMID: 28956187.

10: Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y,
Takahashi T, Katakami N, Inoue A, Yano S. Phase I study of combined therapy with
vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance
in EGFR-mutant lung cancer (VICTROY-J): a study protocol. J Med Invest.
2017;64(3.4):321-325. doi: 10.2152/jmi.64.321. PubMed PMID: 28955007.